



hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 016556-003010US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On May 11, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Ann Honcik Dallara  
Jo Ann Honcik Dallara

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Barber, Jack R. et al.

Application No.: 10/613,565

Filed: July 2, 2003

For: GENE FUNCTIONAL ANALYSIS  
AND DISCOVERY USING  
RANDOMIZED OR TARGET-SPECIFIC  
RIBOZYME GENE VECTOR  
LIBRARIES

Customer No.: 20350

Confirmation No. 5484

Examiner: Gibbs, Terra C.

Technology Center/Art Unit: 1635

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed January 19, 2005, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing filed in Application No. 09/355,221, submitted on March 4, 2003. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/355,221 as the computer-readable form for the instant application. The information in the paper copy of the

Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Included with this response is a request for a one-month extension of time in which to respond, and a Terminal Disclaimer for prior Patent No. 6,605,429.

Please amend the specification as follows.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 7 of this paper.

**Remarks/Arguments** begin on page 17 of this paper.